Literature DB >> 28847701

Invasive meningococcal disease: Impact of short course therapy. A DOOR/RADAR study.

Carmen Cabellos1, Ivan Pelegrín2, Eva Benavent3, Francesc Gudiol3, Fe Tubau4, Dolores Garcia-Somoza4, Ricard Verdaguer4, Javier Ariza3, Pedro Fernandez-Viladrich3.   

Abstract

BACKGROUND: Invasive meningococcal disease is a severe infection. The appropriate duration of antibiotic therapy is not well established.
METHODS: Two hundred and sixty-three consecutive patients with invasive meningococcal disease treated with 4 days' antibiotic therapy were compared with 264 consecutive patients treated previously at the same center with 7 days' antibiotic therapy. A Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR) study was also performed.
RESULTS: No relapses were recorded in any patient. Patients on the 4-day course were 63% female, with a median age of 23 years old (IQR 16-54) and patients on the 7-day course were 61% female, with a median age of 17 years old (IQR 12-43). Case fatality rate was 7% in the 4-d patients and 6% in the 7-d patients (p = 0.582). Neurological sequelae were recorded in 6% of the 4-d group and in 7% of the 7-d group ((p = 0.509) and cutaneous sequelae in 3% in both groups. There were no statistical significant differences between the groups in terms of clinical characteristics, laboratory findings or complications. The probability that a patient had a randomly chosen DOOR better with the 4-day regimen than with the 7-day regimen was 80.4% [95% CI 80.1-80.7%].
CONCLUSION: Invasive meningococcal disease may be successfully treated with a four-day course of antibiotic therapy without relapses.
Copyright © 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic therapy; Bacterial meningitis; DOOR/RADAR; Neisseria meningitidis

Mesh:

Substances:

Year:  2017        PMID: 28847701     DOI: 10.1016/j.jinf.2017.08.009

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  2 in total

1.  Outcomes of adults with invasive meningococcal disease with reduced penicillin susceptibility in Auckland 2004-2017.

Authors:  Matthew Broom; Emma Best; Helen Heffernan; Sara Svensson; Maria Hansen Hygstedt; Rachel Webb; Nick Gow; David Holland; Mark Thomas; Simon Briggs
Journal:  Infection       Date:  2022-08-18       Impact factor: 7.455

2.  Invasive Meningococcal Disease: What We Should Know, Before It Comes Back.

Authors:  Carmen Cabellos; Ivan Pelegrín; Eva Benavent; Francesc Gudiol; Fe Tubau; Dolores Garcia-Somoza; Ricard Verdaguer; Javier Ariza; Pedro Fernandez Viladrich
Journal:  Open Forum Infect Dis       Date:  2019-02-07       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.